Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5

References

• Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human CYP enzymes using LC-MS-MS analysis. Drug Metabolism and Disposition 2005; 33: 1637–1647
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interaction. Clinical Pharmacokinetics 1997; 32: 210–258
   PubMed Web of Science ®Google Scholar
• De Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues. Journal of Pharmacology and Experimental Therapy 1990; 253: 387–394
   PubMed Web of Science ®Google Scholar
• Ekins S, Stresser DM, Wiliams JA. In vitro and pharmacophore insights into CYP3A enzymes. Trends in Pharmacology Science 2004; 24: 161–166
   Web of Science ®Google Scholar
• Ernest CS, II, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology and Experimental Therapy 2005; 312: 583–591
   PubMed Web of Science ®Google Scholar
• Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR. Genotype–phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European and African-American men and women. Pharmacogenetics 2003; 13: 595–606
   PubMedGoogle Scholar
• Foti RS, Fisher MB. Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials. Pharmacogenetics Journal 2003; 4: 362–364
   Web of Science ®Google Scholar
• Galetin A, Brown C, Halifax D, Ito K, Houston JB. Utility of recombinant enzyme kinetics in prediction of human clearance: Impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metabolism and Disposition 2004; 32: 1411–1420
   PubMed Web of Science ®Google Scholar
• Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J, Schuetz E, Lim R, Lim H-L, Ong A-B, Lee H-S. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. Journal of Clinical Oncology 2002; 20: 3683–3690
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, Vandenbranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemistry and Pharmacology 1994; 47: 1643–1653
   PubMed Web of Science ®Google Scholar
• Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD. Bimodal distribution of renal cytochrome P450 3A activity in humans. Molecular Pharmacology 1996; 50: 52–59
   PubMed Web of Science ®Google Scholar
• Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, Sugiyama Y. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharmacology and Drug Disposition 2001; 22: 53–71
   PubMed Web of Science ®Google Scholar
• Huang W, Lin YS, McConn DJ, II, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metabolism and Disposition 2004; 32: 1434–1445
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metabolism and Disposition 2003; 31: 243–249
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4. Drug Metabolism and Disposition 2002; 30: 985–990
   PubMed Web of Science ®Google Scholar
• Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metabolism and Disposition 2002; 30: 1108–1114
   PubMed Web of Science ®Google Scholar
• Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabolism and Disposition 1998; 26: 552–561
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel KE, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001; 27: 383–391
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 2002; 62: 162–172
   PubMed Web of Science ®Google Scholar
• MacPhee IAM, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, Holt DW. Tacrolimus pharmacogenetics: The CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499–502
   PubMed Web of Science ®Google Scholar
• Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clinical Pharmacology and Therapy 2004; 76: 341–349
   PubMed Web of Science ®Google Scholar
• McConn DJ II, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite–inhibitor complex-forming drugs. Drug Metabolism and Disposition 2004; 32: 1083–1091
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Griffin SJ, Moody GC, Voice M, Hanlon S, Friedberg T, Riley RJ. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metabolism and Disposition 1999; 27: 1017–1023
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Parker AJ, Soars M, Riley RJ. Automated definition of enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 2000; 28: 1327–1334
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metabolism and Disposition 2004; 32: 1247–1253
   PubMed Web of Science ®Google Scholar
• Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica 1999; 29: 53–75
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapy 1997; 283: 1552–1562
   PubMed Web of Science ®Google Scholar
• Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metabolism and Disposition 2003; 31: 938–944
   PubMed Web of Science ®Google Scholar
• Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004; 34: 151–178
   PubMed Web of Science ®Google Scholar
• Riley RJ. The potential pharmacological and toxicological impact of P450 screening. Current Opinions in Drug Discovery and Development 2001; 3: 30–41
   Google Scholar
• Shih P-S, Huang J-D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metabolism and Disposition 2002; 30: 1491–1496
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapy 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Soars MG, Gelboin HV, Krausz KW, Riley RJ. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. British Journal of Clinical Pharmacology 2002; 55: 175–181
   Web of Science ®Google Scholar
• Thervet E, Anglicheau D, King B, Schlageter M-H, Cassinat B, Beaune P, Legendre C, Daly AK. Impact of Cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233–1235
   PubMed Web of Science ®Google Scholar
• Thummel KE. Does the CYP3A5*3 polymorphism affect in vivo drug elimination?. Pharmacogenetics 2003; 13: 585–587
   PubMedGoogle Scholar
• Wang Y-H, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metabolism and Disposition 2005; 33: 664–671
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metabolism and Disposition 2003; 31: 755–761
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions. Clinical Pharmacology and Therapy 2004; 76: 99–103
   PubMed Web of Science ®Google Scholar
• Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5?. Drug Metabolism and Disposition 2003; 31: 1526–1531
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition 2002; 30: 883–891
   PubMed Web of Science ®Google Scholar
• Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clinical Pharmacology and Therapy 2004; 75: 529–538
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology 1992; 22: 1–22
   PubMed Web of Science ®Google Scholar
• Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metabolism and Pharmacokinetics 2004; 19: 120–129
   PubMedGoogle Scholar
• Yu K-S, Cho J-Y, Jang I-J, Hong K-S, Chung J-Y, Kim J-R, Lim H-S, Oh D-S, Yi S-Y, Liu K-H, Shin J-G, Shin S-G. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clinical Pharmacology and Therapy 2004; 76: 104–112
   PubMed Web of Science ®Google Scholar
• Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. American Journal of Transplantation 2003; 3: 477–483
   PubMed Web of Science ®Google Scholar